Trustco Bank Corp N Y Reduces Position in Pfizer Inc. (NYSE:PFE)

Trustco Bank Corp N Y lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,343 shares of the biopharmaceutical company’s stock after selling 1,199 shares during the period. Trustco Bank Corp N Y’s holdings in Pfizer were worth $487,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of PFE. Tallon Kerry Patrick purchased a new stake in Pfizer during the 4th quarter valued at about $509,000. Merit Financial Group LLC grew its stake in Pfizer by 60.8% during the 4th quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock valued at $3,395,000 after acquiring an additional 48,397 shares in the last quarter. Sax Wealth Advisors LLC grew its stake in Pfizer by 17.4% during the 4th quarter. Sax Wealth Advisors LLC now owns 10,995 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 1,630 shares in the last quarter. Lake Street Private Wealth LLC boosted its holdings in Pfizer by 8.3% in the 4th quarter. Lake Street Private Wealth LLC now owns 10,096 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 776 shares during the last quarter. Finally, Ameritas Advisory Services LLC boosted its holdings in Pfizer by 3.6% in the 4th quarter. Ameritas Advisory Services LLC now owns 75,983 shares of the biopharmaceutical company’s stock valued at $2,016,000 after purchasing an additional 2,633 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price on the stock. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Stock Performance

Shares of PFE stock opened at $22.83 on Monday. The firm’s 50 day moving average price is $23.65 and its 200-day moving average price is $25.32. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The firm has a market cap of $129.77 billion, a P/E ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the business posted $0.82 EPS. The business’s revenue for the quarter was down 7.8% compared to the same quarter last year. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.54%. The ex-dividend date is Friday, May 9th. Pfizer’s payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.